Skip to main content
| News

Bachem builds its largest production building

11.11.2021

Bachem has laid the foundation stone for its largest production building to date. The company specializing in the manufacture of peptides and oligonucleotides will initially create up to 150 new skilled jobs with this. This will strengthen the position of Bubendorf, located in the Basel Area, as a center of excellence.

Bachem Bubendorf
Bachem is specializing in the manufacture of peptides and oligonucleotides (img: Bachem)

Bachem has started construction of the world’s most high-tech production building for peptides and oligonucleotides at its location in Bubendorf in the canton of Basel-Landschaft. The foundation stone was laid on Thursday. According to a press release, the building should expand the production capacities for these complex molecules by 2024 at the latest. These substances are used in medicinal products used to treat various diseases.

In a first phase, up to 150 positions, most of which will be highly skilled, are to be created there. The listed company has invested over 150 million Swiss francs and created 400 new jobs at its two sites in Bubendorf and Vionnaz (in the canton of Valais) over the past five years. The new production building will now strengthen the Bubendorf site’s position as a “leading center of excellence for the manufacture of complex pharmaceutical active ingredients” according to the press release. Additionally, it represents a clear commitment to Switzerland and Basel Area as a location.

Since global demand for these molecules is constantly increasing, Bachem is already looking for a third production site in Switzerland. The land reserves at the Bubendorf site will be exhausted in the medium term.

The company celebrated its 50th anniversary this year. CEO Thomas Meier is delighted that the foundation stone was laid on Swiss National Future Day, which is a day for young people to learn about working in a company. Meier adds: “Our success is founded on our ability to invest into our company efficiently and with foresight, but also on the ability to excite new generations for the impact chemistry and the natural sciences can have.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

BSI integrating AI from Parashift in banking software

Parashift, the specialist in the area of smart document processing on the basis of Artificial Intelligence (AI), has entered into...

Read More
1 2 3 60

Do you have a question? We'd like to hear from you.